Abstract
BackgroundThe aim of this study was to explore the relationships between depressive symptoms and health-related quality of life (HRQOL) measurements for inpatients with major depressive disorder (MDD) before and after 6-week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes.MethodsA total of 131 inpatients with MDD were enrolled to receive 20 mg of fluoxetine for 6 weeks. Symptom severity and adverse events were assessed at weeks 0, 1, 2, 3, 4, and 6 using the 17-item Hamilton Depression Rating Scale (HAMD-17) and UKU Side Effect Rating Scale, respectively. HRQOL was measured using the Short Form 36 (SF-36), including 8 subscales, physical component summary (PCS) and mental component summary (MCS), at baseline and week 6. Spearman’s coefficient, Cohen’s d, and multiple linear regression model were used for statistical analysis.ResultsOne hundred and six patients completing all measures at weeks 0 and 6 entered the analysis. HAMD-17 negatively correlated with SF-36 at baseline and week 6. The HAMD-17 had a larger effect size than SF-36. MCS, rather than PCS, showed statistically significant improvement. After using multiple linear regression analysis, age at onset, HAMD-17 score change, and number of adverse events reported during the trial period were related to MCS change after adjusting for confounding variables.ConclusionsFluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL. Depressive symptoms had a greater extent of change than HRQOL. Clinicians must consider the negative effects of adverse events caused by antidepressants on the improvement of HRQOL.Trial registrationhttp://clinicaltrials.gov, NCT01075529, retrospectively registered 24/2/2010.
Highlights
The aim of this study was to explore the relationships between depressive symptoms and healthrelated quality of life (HRQOL) measurements for inpatients with major depressive disorder (MDD) before and after 6-week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes
The aim of this study was to explore the relationships between depressive symptoms and HRQOL measurements for MDD inpatients before and after a 6week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes
The current study shows that the amelioration of depressive symptoms measured by 17-item Hamilton Depression Rating Scale (HAMD-17) was still accompanied by improvements in mental component summary (MCS) after adjusting for other variables (Table 4)
Summary
The aim of this study was to explore the relationships between depressive symptoms and healthrelated quality of life (HRQOL) measurements for inpatients with major depressive disorder (MDD) before and after 6-week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes. Health-related quality of life (HRQOL) has been defined as “those aspects of self-perceived well-being that are related to or affected by the presence of disease or treatment [1].”. The assessment of HRQOL should consider patients’ subjective views of their life circumstances [2], including perceptions of social relationships, physical health, mental heath, functioning in daily activities and work, and an overall sense of well-being [3]. HRQOL measurement should consider patients’ subjective views of their life circumstances [8]. This may provide a more extensive assessment of treatment outcomes than those based solely on improvement in symptoms of depression. While antidepressant medication may decrease depressive symptoms, it may induce unpleasant adverse events that impair the
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
